Characterization of V3 loop-Pseudomonas exotoxin chimeras -: Candidate vaccines for human immunodeficiency virus-1

被引:14
|
作者
Fitzgerald, DJ
Fryling, CM
McKee, ML
Vennari, JC
Wrin, T
Cromwell, MEM
Daugherty, AL
Mrsny, RJ
机构
[1] NCI, NIH, Biotherapy Sect, Mol Biol Lab,Div Basic Sci, Bethesda, MD 20892 USA
[2] Genentech Inc, Pharmaceut Res & Dev, Cell Banking, S San Francisco, CA 94080 USA
[3] Genentech Inc, Pharmaceut Res & Dev, Drug Delivery Biol, S San Francisco, CA 94080 USA
关键词
D O I
10.1074/jbc.273.16.9951
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To develop a candidate vaccine for human immunodeficiency virus, type 1 (HIV-1), chimeric proteins were constructed by inserting sequences derived from the V3 loop of gp120 into a nontoxic form of Pseudomonas exotoxin (PE). Inserts of 14 or 26 amino acids, constrained by a disulfide bond, were introduced between domains II and III of PE. V3 loop-toxin proteins expressed in Escherichia coli and corresponding to either MN (subtype B) or Thai (subtype E) strains, were recognized by strain-specific monoclonal anti-gp120 antibodies. When loop sequences were introduced into an enzymatically active form of the toxin, there was no loss of toxin-mediated cell killing, suggesting that these sequences were co-transported to the cytosol. Sera from rabbits injected with nontoxic PE-V3 loop chimeras were reactive for strain-specific gp120s in Western blots, immunocapture assays, enzyme-linked immunosorbent assays, and neutralized HIV-1 infectivity. Since toxin vectors were designed to receive oligonucleotide duplexes encoding any V3 loop sequence, this approach should allow for the production of V3 loop-toxin chimeras corresponding to multiple HIV isolates.
引用
收藏
页码:9951 / 9958
页数:8
相关论文
共 50 条
  • [31] MUTATIONAL TRENDS IN V3 LOOP PROTEIN SEQUENCES OBSERVED IN DIFFERENT GENETIC LINEAGES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    KORBER, BTM
    MACINNES, K
    SMITH, RF
    MYERS, G
    JOURNAL OF VIROLOGY, 1994, 68 (10) : 6730 - 6744
  • [32] Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1
    Aguilar, A
    Carrazana, Y
    Duarte, CA
    BIOMOLECULAR ENGINEERING, 2001, 18 (03): : 117 - 124
  • [33] Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host
    Watabe, T
    Kishino, H
    Okuhara, Y
    Kitazoe, Y
    GENETICS, 2006, 172 (03) : 1385 - 1396
  • [34] Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats
    Tang, Hongmei
    Lu, Daxiang
    Pan, Rui
    Qin, Xuebin
    Xiong, Huangui
    Dong, Jun
    LIFE SCIENCES, 2009, 85 (1-2) : 1 - 10
  • [35] Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1
    Schonning, K
    Jansson, B
    Olofsson, S
    Hansen, JES
    JOURNAL OF GENERAL VIROLOGY, 1996, 77 : 753 - 758
  • [36] Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection
    Nelson, JEA
    Baribaud, F
    Edwards, T
    Swanstrom, R
    JOURNAL OF VIROLOGY, 2000, 74 (18) : 8494 - 8501
  • [37] V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant
    Plantier, JC
    Damond, F
    Souquières, S
    Brun-Vézinet, F
    Simon, F
    Barin, F
    JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (10) : 3803 - 3807
  • [39] Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
    Hung, CS
    Vander Heyden, N
    Ratner, L
    JOURNAL OF VIROLOGY, 1999, 73 (10) : 8216 - 8226
  • [40] Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop
    Hoffman, NG
    Seillier-Moiseiwitsch, F
    Ahn, J
    Walker, JM
    Swanstrom, R
    JOURNAL OF VIROLOGY, 2002, 76 (08) : 3852 - 3864